mbi-226 and Bacteremia

mbi-226 has been researched along with Bacteremia* in 1 studies

Reviews

1 review(s) available for mbi-226 and Bacteremia

Article	Year
MBI-226. Micrologix/Fujisawa. Current opinion in investigational drugs (London, England : 2000), 2003, Volume: 4, Issue:8 Micrologix and Fujisawa are developing a gel formulation of MBI-226 for the potential treatment and prevention of various infections caused by both antibiotic-resistant and -sensitive bacteria. In September 2000, a phase III trial of MBI-226 for the potential prevention of catheter-related bloodstream infections was initiated. Topics: Administration, Topical; Anti-Infective Agents; Antimicrobial Cationic Peptides; Bacteremia; Catheterization, Central Venous; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Skin Absorption; Structure-Activity Relationship	2003

Article

Year

Current opinion in investigational drugs (London, England : 2000), 2003, Volume: 4, Issue:8

Micrologix and Fujisawa are developing a gel formulation of MBI-226 for the potential treatment and prevention of various infections caused by both antibiotic-resistant and -sensitive bacteria. In September 2000, a phase III trial of MBI-226 for the potential prevention of catheter-related bloodstream infections was initiated.

Topics: Administration, Topical; Anti-Infective Agents; Antimicrobial Cationic Peptides; Bacteremia; Catheterization, Central Venous; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Skin Absorption; Structure-Activity Relationship

2003

Trials

1 trial(s) available for mbi-226 and Bacteremia

Article	Year
MBI-226. Micrologix/Fujisawa. Current opinion in investigational drugs (London, England : 2000), 2003, Volume: 4, Issue:8 Micrologix and Fujisawa are developing a gel formulation of MBI-226 for the potential treatment and prevention of various infections caused by both antibiotic-resistant and -sensitive bacteria. In September 2000, a phase III trial of MBI-226 for the potential prevention of catheter-related bloodstream infections was initiated. Topics: Administration, Topical; Anti-Infective Agents; Antimicrobial Cationic Peptides; Bacteremia; Catheterization, Central Venous; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Skin Absorption; Structure-Activity Relationship	2003